Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + cabozantinib versus docetaxel in previously treated metastatic non-small cell lung cancer
2020-000100-11Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Atezolizumab + cabozantinib with Docetaxel monotherapy (2 arms). Primary endpoint: Overall survival. Started Jul 2020; status: completed.
02
Drugs
atezolizumabcabozantinibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-000100-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000100-11.